BRPI0913214A2 - sistema de fornecimento de drogas transdérmico estabilizado - Google Patents

sistema de fornecimento de drogas transdérmico estabilizado

Info

Publication number
BRPI0913214A2
BRPI0913214A2 BRPI0913214A BRPI0913214A BRPI0913214A2 BR PI0913214 A2 BRPI0913214 A2 BR PI0913214A2 BR PI0913214 A BRPI0913214 A BR PI0913214A BR PI0913214 A BRPI0913214 A BR PI0913214A BR PI0913214 A2 BRPI0913214 A2 BR PI0913214A2
Authority
BR
Brazil
Prior art keywords
delivery system
drug delivery
transdermal drug
stabilized
stabilized transdermal
Prior art date
Application number
BRPI0913214A
Other languages
English (en)
Inventor
Jiashang Tang
Original Assignee
Mylan Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41380695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913214(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mylan Lab Inc filed Critical Mylan Lab Inc
Publication of BRPI0913214A2 publication Critical patent/BRPI0913214A2/pt
Publication of BRPI0913214B1 publication Critical patent/BRPI0913214B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10—Methods of surface bonding and/or assembly therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0913214-7A 2008-05-30 2009-05-29 Dispositivo de fornecimento de drogas transdérmico e método de fabricação do mesmo BRPI0913214B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5745508P 2008-05-30 2008-05-30
US61/057,455 2008-05-30
PCT/US2009/045739 WO2009158120A2 (en) 2008-05-30 2009-05-29 Stabilized transdermal drug delivery system

Publications (2)

Publication Number Publication Date
BRPI0913214A2 true BRPI0913214A2 (pt) 2016-01-19
BRPI0913214B1 BRPI0913214B1 (pt) 2022-05-17

Family

ID=41380695

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913214-7A BRPI0913214B1 (pt) 2008-05-30 2009-05-29 Dispositivo de fornecimento de drogas transdérmico e método de fabricação do mesmo

Country Status (11)

Country Link
US (2) US9226902B2 (pt)
EP (1) EP2299989B1 (pt)
JP (2) JP5695562B2 (pt)
KR (1) KR101590209B1 (pt)
CN (1) CN102099020B (pt)
AU (2) AU2009262871B2 (pt)
BR (1) BRPI0913214B1 (pt)
CA (1) CA2726136C (pt)
MX (1) MX2010012989A (pt)
NZ (1) NZ589542A (pt)
WO (1) WO2009158120A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913214B1 (pt) * 2008-05-30 2022-05-17 Mylan Laboratories Inc Dispositivo de fornecimento de drogas transdérmico e método de fabricação do mesmo
CN102630160B (zh) * 2009-09-16 2014-05-07 株式会社三养生物制药 透皮递送系统、其制备方法以及使用所述系统的透皮递送方法
WO2011076879A1 (en) * 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
CN104582693A (zh) * 2012-08-15 2015-04-29 道康宁公司 多层药物递送系统
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
WO2015025767A1 (ja) * 2013-08-21 2015-02-26 久光製薬株式会社 貼付剤
RS58759B1 (sr) 2014-01-22 2019-06-28 4P Therapeutics Transdermalni sistemi koji onemogućavaju zloupotrebu i pogrešnu upotrebu
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
WO2016049266A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
KR102241892B1 (ko) 2017-01-25 2021-04-20 한국전자기술연구원 백스캐터 통신을 위한 데이터 부호화 방법 및 이를 위한 장치
CN108785286A (zh) * 2017-04-28 2018-11-13 日东电工株式会社 透皮吸收制剂
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
EP3925606B1 (en) * 2019-02-15 2026-03-11 Hisamitsu Pharmaceutical Co., Inc. Rotigotine stabilization method
WO2020189323A1 (ja) 2019-03-19 2020-09-24 ノーベルファーマ株式会社 薬物の生体への吸収性に優れ、且つ、化学的安定性にも優れる医薬組成物
EP3976003A1 (en) * 2019-05-31 2022-04-06 Kindeva Drug Delivery L.P. Removable film-forming gel compositions featuring adhesion promoters
US20220370374A1 (en) * 2019-10-16 2022-11-24 Kyushu University, National University Corporation Transdermal absorption-type patch
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof
WO2022045335A1 (ja) * 2020-08-31 2022-03-03 ノーベルファーマ株式会社 神経変性疾患の症状の緩和又は治療のための貼付剤
CN112891324A (zh) * 2021-01-19 2021-06-04 北京亚宝生物药业有限公司 一种透皮贴剂
KR102363479B1 (ko) * 2021-03-12 2022-02-15 환인제약 주식회사 로티고틴 함유 경피 흡수 제제
JP2024520271A (ja) * 2021-06-06 2024-05-24 スタートン セラピューティクス インコーポレイテッド 治療上有効な量のレナリドミドまたは他の免疫調節剤を投与するための経皮薬物送達システム
CN113648297B (zh) * 2021-08-16 2023-07-14 乐明药业(苏州)有限公司 一种含有氟比洛芬的药物组合物与贴剂
JP2025541579A (ja) * 2022-12-26 2025-12-19 ホワン イン ファーマシューティカル カンパニー リミテッド 経皮吸収用製剤およびその製造方法
WO2026064519A1 (en) * 2024-09-18 2026-03-26 Kalm Therapeutics Inc. Compositions and methods for articles comprising therapeutic agents

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
DE3204551A1 (de) * 1982-02-10 1983-08-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung einer pharmazeutischen zubereitung in form eines polyacrylat-films
JPS60169414A (ja) 1984-02-14 1985-09-02 Taisho Pharmaceut Co Ltd 経皮吸収剤
US4880633A (en) * 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
ATE194281T1 (de) * 1994-09-14 2000-07-15 Minnesota Mining & Mfg Matrix für transdermale wirkstofffreisetzung
US5662928A (en) * 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
KR970009795A (ko) * 1995-08-30 1997-03-27 이웅열 경피투여용 첩부제 조성물
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US6238700B1 (en) * 1995-12-01 2001-05-29 Alza Corporation Method for preventing crystal formation in a dispersion of a liquid in a matrix
WO1997020550A2 (en) * 1995-12-01 1997-06-12 Alza Corporation Improved method for preventing crystal formation in a dispersion of a liquid in a matrix
DE19548332A1 (de) * 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
US6623763B2 (en) * 1996-01-08 2003-09-23 Lts Lohmann Therape-System Ag Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism
US5869089A (en) * 1996-03-21 1999-02-09 China-America Technology Corp. (Ctc) Manufacturing method of programmable transdermal therapeutic system
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
WO2005123046A1 (en) * 2004-06-15 2005-12-29 Amorepacific Corporation Novel transdermal preparation and its producing method
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20060188558A1 (en) 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
WO2007077741A1 (ja) 2005-12-28 2007-07-12 Hisamitsu Pharmaceutical Co., Inc. 経皮吸収型製剤
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
WO2008128126A1 (en) * 2007-04-11 2008-10-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
BRPI0913214B1 (pt) * 2008-05-30 2022-05-17 Mylan Laboratories Inc Dispositivo de fornecimento de drogas transdérmico e método de fabricação do mesmo
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法

Also Published As

Publication number Publication date
KR101590209B1 (ko) 2016-02-01
WO2009158120A2 (en) 2009-12-30
US20090299304A1 (en) 2009-12-03
EP2299989B1 (en) 2019-01-02
AU2016202212B2 (en) 2018-05-10
AU2009262871A1 (en) 2009-12-30
US20110182949A1 (en) 2011-07-28
BRPI0913214B1 (pt) 2022-05-17
US9226902B2 (en) 2016-01-05
JP5695562B2 (ja) 2015-04-08
CN102099020A (zh) 2011-06-15
KR20110025931A (ko) 2011-03-14
JP2011521974A (ja) 2011-07-28
EP2299989A2 (en) 2011-03-30
WO2009158120A3 (en) 2010-03-04
JP2015083569A (ja) 2015-04-30
CA2726136C (en) 2016-11-01
NZ589542A (en) 2012-10-26
MX2010012989A (es) 2011-04-27
EP2299989A4 (en) 2013-11-13
AU2016202212A1 (en) 2016-05-12
CN102099020B (zh) 2013-09-18
AU2009262871B2 (en) 2016-04-14
CA2726136A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
BRPI0917030A2 (pt) sistema de liberação de fármaco contendo progestina
BRPI0819245A2 (pt) sistema de distribuição transdérmica
BRPI0912144A2 (pt) configuração de sistema de infusão
EP2299989A4 (en) STERILIZED TRANSDERMAL DRUG DELIVERY SYSTEM
BRPI0913008A2 (pt) dispositivo de administração de medicação
DK2185220T3 (da) Anordning til lægemiddelfremføring
BRPI0908231A2 (pt) Sistema de liberação de fármaco com efeito estabilizante
DK2274030T4 (da) Lægemiddelafgivelsesanordning
DK3756657T3 (da) Synkbar anordning til lægemiddelfremføring
DK2398500T3 (da) Glutathion-baseret lægemiddelafgivelsessystem
BRPI1010279A2 (pt) dispositivo de distribuição de fármaco
DK2355867T3 (da) Anordning til medikamentafgivelse
DK2274029T3 (da) Lægemiddelafgivelsesanordning
BR112013012818A2 (pt) módulo medicamentoso e sistema de administração de fármaco
BRPI1012730A2 (pt) dispositivo de distribuição de fármaco
BRPI0909653A2 (pt) sistema terapêutico transdérmico com membrama estabilizada
DK2296732T3 (da) Medikamentafgivelsesindretning
BRPI0920690A2 (pt) sistema de distribuição de stent restringível
DK2493532T3 (da) Lægemiddelfremføringsanordning
BRPI0920514A2 (pt) infusão de fármacos
BRPI1010237A2 (pt) dispositivo de distribuição de fármaco
BRPI1014975A2 (pt) sistema de entrega de implante
BRPI0813090A2 (pt) Sistema de injeção de autoadministração
DK2381988T3 (da) Medikamentadministrationsanordning
ATE485035T1 (de) Transdermales arzneimittelabgabesystem für flüssige aktivsubstanzen

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.